Key Studies in Skin Cancer: Independent Conference Coverage of the 2022 ASCO Annual Meeting
  • CME

June 3-7, 2022; Chicago, Illinois
Review expert perspectives on the most clinically relevant data on skin cancers presented at the 2022 ASCO Annual Meeting.
Allison Betof Warner, MD, PhD
Hussein Tawbi, MD, PhD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: August 29, 2022 Expiration: August 28, 2023

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with skin cancer
  • Identify subpopulations of patients with skin cancer most likely to benefit from a specific treatment plan based on predictive biomarkers
  • Evaluate new data on novel agents and therapeutic approaches for patients with skin cancer

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Merck Sharp & Dohme Corp.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Allison Betof Warner, MD, PhD

Assistant Member
Assistant Attending Physician
Melanoma Service
Division of Tumor Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Allison Betof Warner, MD, PhD: consultant/advisor/speaker: Bristol-Myers Squibb, Instil Bio, Iovance, Lyell Immunopharma, Novartis, Pfizer, Shanghai Jo’Ann Medical Technology.
Hussein Tawbi, MD, PhD

Associate Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Hussein Tawbi, MD, PhD: researcher: Bristol-Myers Squibb, Dragonfly Therapeutics, Eisai, EMD Serono, Genentech, GlaxoSmithKline, Merck, Novartis, RAPT Therapeutics.

Staff

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant financial relationships to disclose.
Kara Nyberg, PhD

Editorial Contributor

Kara Nyberg, PhD, has no relevant financial relationships to disclose.
Timothy A. Quill, PhD

Vice President, Scientific Services

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant financial relationships to disclose.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with skin cancer

Goal

The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with skin cancer

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 29, 2022, through August 28, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Commenti di esperti sui dati della Conferenza annuale della SOHO 2022 sugli inibitori di BTK per il trattamento di CLL e MCL, a cura di Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Comentario experto de los datos de la Junta Anual de SOHO 2022 sobre inhibidores de la TQB para LLC y LCM de Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Expertengespräch über die Daten der Jahresversammlung der SOHO 2022 zu BTK-Inhibitoren bei CLL und MCL, von Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Comentários de especialistas sobre dados da Reunião Anual da SOHO 2022 sobre os inibidores de BTK para LLC e LCM, do Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings